Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study.

Exploring the Long-Term Efficacy and Safety of Leflunomide Combined with Prednisone in Myasthenia Gravis

Myasthenia gravis (MG) is a chronic autoimmune disorder that affects the neuromuscular junction. This study retrospectively investigated the long-term efficacy and safety of combining leflunomide (LEF) with low-dose prednisone (Pred) in the treatment of MG. The researchers analyzed data from MG patients treated with LEF+Pred at their center between 2012 and 2020, focusing on clinical outcomes, including MG activities of daily living (MG-ADL) scores, quantitative MG scale (QMG) scores, and adverse effects. The study sought to assess the long-term effectiveness and safety of this combination therapy in managing MG.

LEF+Pred: A Promising Combination Therapy for MG

The study demonstrated that long-term treatment with LEF+Pred resulted in significant improvement in clinical symptoms for MG patients, with 88.4% of patients achieving effective treatment after 12 months. The average MG-ADL and QMG scores significantly decreased, indicating a substantial improvement in functional capacity and overall disease severity. The study also found that LEF+Pred was well tolerated with only a limited number of minor adverse effects. This research suggests that LEF+Pred may be an effective and well-tolerated long-term treatment option for MG patients.

Managing MG: A Dr. Camel's Perspective

Imagine a desert traveler carrying a heavy load, Their muscles fatigue, their movements become strained. MG, like a persistent desert wind, can weaken the traveler's strength and make their journey difficult. LEF+Pred, like a sturdy camel, can help the traveler carry their burden, providing support and strength to continue their journey with greater ease.

Dr. Camel's Conclusion

This retrospective study provides encouraging evidence for the long-term efficacy and safety of LEF+Pred in the treatment of MG. The study highlights the potential benefits of this combination therapy in improving clinical symptoms, functional capacity, and overall disease severity. It underscores the importance of exploring new and effective treatment options for MG patients, promoting their quality of life and facilitating their continued journey through life's desert.